Affymax Largely Ducks Investor Suit Over Anemia Drug

Law360, Washington (January 22, 2014, 1:52 PM EST) -- A California federal judge on Tuesday trimmed a putative shareholder class action claiming Affymax Inc. and four executives misled investors about safety issues with anemia drug Omontys, ruling the plaintiffs hadn’t shown most of the statements were intentionally misleading.

U.S. District Judge William Orrick determined that two of the three statements that plaintiffs pointed to in their complaint may not be false or misleading and tossed most of the suit, but he allowed some allegations to move forward based on a February 2013 conference call between Affymax CEO John...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Carter v. Affymax, Inc. et al


Case Number

3:13-cv-01025

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

William H. Orrick

Date Filed

March 6, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.